The greatest challenges for surgical management of cancer are precisely locating lesions and clearly defining the margins between tumors and normal tissues. This is confounded by the characteristics of the tissue where the tumor is located as well as its propensity to form irregular boundaries with healthy tissues. To address these issues, molecularly targeted optical contrast agents have been developed to define margins in real-time during surgery 1,2 . However, selectivity of a contrast agent is often limited by expression of a target enzyme or receptor in both tumor and healthy tissues. Here we introduce a concept of multivariate 'AND-gate' optical imaging probes that require sequential processing by multiple tumor-specific enzymes to produce a fluorescent signal. This results in dramatically improved specificity as well as overall enhanced sensitivity. This general approach has the potential to be broadly applied to selectively target complex patterns of enzyme activities in diverse disease tissues for detection, treatment and therapy response monitoring. AND-Gate probes. Thanks to Michael P. Luciano and Martin J. Schnermann at the National Cancer Institute for supplying the FNIR-Tag-OSu used to synthesize the AND-Gate-FNIR probe. Thanks to the Peter Santa Maria Lab for using their SpectraM2 plate reader. AUTHOR CONTRIBUTIONS M.B. and J.C.W conceived of the AND-Gate probe concept and designed all experiments. J.C.W synthesized all AND-Gate probes, conducted the fluorogenic substrate assays, live and fixed cell fluorescent microscopy experiments, and mouse model experiments. J.C.W and M.B. wrote the text of the paper and constructed the figures with input from J.J.Y., M.T., and J.J.Y helped perform live and ex vivo imaging during the 4T1 cancer mouse model experiment including dissection of the mice. M.T. aided in the immunohistochemical analysis of 4T1 tumors. A.A, A.K., and J.S. assisted with the robotic surgery. S.R. assisted in the colorectal cancer mouse model. K.M.C. evaluated H&E sections for the colorectal and 4T1 breast cancer mouse models.
Introduction
For many cancers, surgery is the primary treatment option followed by chemo and/or radiation therapy. Early detection and surgical removal of solid tumors currently remain the most effective way to produce a curative result. Success outcomes are highly dependent on how effectively the tumor tissue can be identified 2, 3 . Accurate detection of the 'margin' between tumor and normal healthy tissues is essential to prevent either incomplete removal of tumor cells leading to increased recurrence rates (up to 30-65% of cases) [4] [5] [6] or removal of excess healthy tissue.
Furthermore, solid tumors derived from different tissues and cell types can have dramatically different margin borders, making the prospects for complete removal highly variable 7 . In fact, rates of repeat surgeries for some cancer types (i.e. breast) can be as high as 50% 3, 8 .
Therefore, new methods that allow both selective and sensitive real-time detection of tumor margins have the potential to significantly impact surgical treatment outcomes of many of the most common types of cancer.
For most surgical treatments for cancer, imaging methods such as MRI, PET, SPECT and CT are used to diagnose and then identify the location of tumors 9 . However, these methods are not easily used intra-operatively due to the need for large instrumentation and/or ionizing radiation. They also typically do not provide sufficient sensitivity and resolution to allow identification of microscopic processes at the tumor margin. Alternatively, various analytical methods can be used to detect specific molecular signatures in real-time during a surgical procedure. This includes the use of mass spectrometry (MS), radio frequency (RF), ultrasound and fluorescence lifetime detectors that allow measurement of specific analytical signatures in the tumor microenvironment that set it apart from the surrounding normal tissues [10] [11] [12] . However, while these types of real-time analytical devices can be highly sensitive and accurate, they all are limited by issues related to sampling error and slow processing times since they require scanning of regions suspected to contain residual cancer.
As an alternative to the use of analytical detectors to scan tissues, systemically delivered optical contrast agents have the potential to broadly highlight tumor sites without any prior knowledge of tumor location. Currently, there are only a few optical agents that are FDA approved for use in humans and that are suitable for use with clinical camera systems. While there has been significant clinical benefit from dyes such as ICG 13 and 5-ALA 14 , the main limitation is their overall non-specific mechanism of action resulting in insufficient sensitivity and selectivity for use in diverse cancer types. A number of pre-clinical and early-stage clinical trials have begun for fluorescently tagged affinity agents such as antibodies, peptides and small molecule ligands 1, 2, 15 . There have also been significant advances in the development of "smart" probes that only produce a fluorescent signal when processed by a tumor-specific enzyme (Fig.   1a ). This leads to a further increase in contrast because free probe outside the tumor remains unprocessed and is not fluorescent. Proteases have become the enzymes of choice for generation of smart probes because short peptide substrates can be decorated with suitable fluorophore/quencher pairs such that probes are optically silent until cleaved by a protease [16] [17] [18] [19] .
Protease activity can also be used to process probes that then change their localization to be retained in cells within the tumor microenvironment 18, 20 . Multiple proteases have proven to be useful biomarkers of cancerous tissues [21] [22] [23] [24] .
Previously, we designed a cysteine cathepsin-cleavable NIR substrate probe 6QC-NIR 20 . Cleavage of this substrate probe produces high signals in cancers of the lung, breast, and colon, which can be detected with the FDA-approved da Vinci ® Si Surgical System equipped with the Firefly ® detection system 20 . We have found that further optimization of the reporter dye on this probe can greatly enhance its use with clinical camera systems 25 . However, the single biggest limitation to the use of protease substrates is their lack of selectivity that results from activity of a protease or protease family in healthy tissues as well as inside the tumor microenvironment. Here we describe a way to dramatically increase the overall tumor-selectivity by designing multivariate 'AND-gate' probes in which multiple reporters must be sequentially processed within the tumor microenvironment to produce a specific optical signal ( Fig. 1b, c) . Thus, selectivity can be greatly enhanced because identification of the tumor tissue is made using multiple markers that help to distinguish it from the surrounding normal tissues. In the current study, we demonstrate the utility of the approach using a probe that contains substrates for both the lysosomal cysteine cathepsins found in tumor associated macrophages and caspases that are activated only in apoptotic cells. The resulting AND-gate probes have greatly improved tumor selectivity due to the relatively high levels of apoptosis in tumors compared to surrounding normal healthy tissues. In addition, we find that AND-gate probes have increased signal accumulation compared to the corresponding cathepsin-only probe.
These improved properties of the AND-gate probes suggest that this will be a general strategy that can be used with diverse enzyme substrates to increase the selectivity of optical contrast agents.
Results

Design, testing and optimization of AND-Gate Probes
The design of a general 'AND-gate' strategy involves placement of a fluorescent reporter in a central location such that multiple quenchers can be attached through linkages that are severed by the action of enzymes. This type of 'hub and spoke' model requires removal of all quenchers along the spokes to liberate the central fluorescent hub. In theory, the quencher groups can be attached to the central hub using any type of enzyme-sensitive linkage resulting in AND-gates that are responsive to a diverse array of enzyme signatures. We choose to test this design strategy using a simple glutamic acid (Glu) central linker containing a fluorescent dye linked to quenchers through distinct peptide sequences that could be orthogonally cleaved by two proteases with non-overlapping substrate specificities. The central Glu linker is ideal because a sulfo-Cy5 fluorophore can be attached to its free α-amine and each peptide substrate containing a sulfo-QSY21 quencher can be connected through amide bonds to the remaining carboxylic acids ( Fig. 2a) . This positions the quenchers such that fluorescence activation occurs only after both peptides have been cleaved. Furthermore, by using diamino-alkyl linkers between the peptides and the Glu core, the final fluorescent fragment will contain two free amine groups that induce lysosomal accumulation of the probe, as we have demonstrated for our cathepsin substrate probes 20 . We chose peptide substrates that have already been shown to be specifically processed by caspase 3 (Casp3; DEVDGP) 26 and the cysteine cathepsins (Cats; Z-FK) 27 . These sequences are optimal for a first generation AND-gate probe because Casp3 and Cats have highly orthogonal substrate specificities and therefore each protease can only process its corresponding substrate. Furthermore, Cats are upregulated in both tumor associated macrophages (TAMs) [28] [29] [30] and in most normal tissues, while Casp3 activity is elevated in tumors but is generally not active in healthy cells, except during development 31 .
Therefore, Cats and Casp3 are both active within tumors but are not expected to be active together in healthy tissues, making them ideal targets for our AND-gate probe strategy.
We synthesized a first-generation probe, AND-Gate 1, containing the natural (L)-Glu central linker ( Fig. 1d, Supplementary Scheme 1) . We also synthesized negative controls in which a (D)-Asp was used in place of the natural (L)-Asp in the P1 position of the Casp3 sequence ((D)-Asp 1) and a (D)-Phe was used in the P2 position of the Cat sequence ((D)-Phe 1). To test the AND-Gate 1 probe, we incubated it with recombinant human CatL, B, S, or Casp3 either separately or sequentially in combinations ( Supplementary Fig. 1a,b) .
Importantly, we found that the probe only produced a fluorescent signal when both cathepsin and Casp3 were incubated sequentially. We also found that both control probes remained nonfluorescent after incubation with both proteases, regardless of order of addition, thus validating the overall concept of the AND-gate strategy (Sup Fig. 1c,d) . We then tested the stability of the linker using total tissue lysates derived from homogenized 4T1 breast tumors (Sup Fig. 1e ). We found that, as expected, the AND-Gate 1 probe was activated and the (D)-Asp 1 negative control remained non-fluorescent. However, the (D)-Phe 1 probe showed robust activation, suggesting a lack of stability at the amide bond connection between the Z-FK substrate and the linker.
Given the instability at the glutamine a-acid, we synthesized a 2 nd generation probe AND-Gate 2 and the respective negative controls (D)-Phe 2 and (D)-Asp 2, in which the natural (L)-Glu was replaced by the unnatural (D)-Glu ( Fig. 2b) . All peptide precursors were synthesized using solid-phase peptide synthesis (SPPS) using standard Fmoc chemistry (see were synthesized in the same manner with similar overall yields.
We evaluated this 2 nd generation set of probes using the in vitro fluorogenic assay with recombinant proteases and found that the probes performed similarly to the first generation probes with only AND-Gate 2 producing signal, and only after addition of both CatL and Casp3 ( Fig. 3a,b ). Using LC-MS analysis, we were able to detect the expected cleavage products after incubation with CatL or Casp3 alone, and with both proteases successively ( Supplementary   Fig. 2) . Importantly, the second-generation probes containing the D-Glu linker showed good stability in tumor lysates, with both negative probes remaining inactive even after 2 hours of incubation ( Fig. 3c) . The AND-gate 2 was also selective for Casp3 over other related initiator and executioner caspases ( Supplementary Fig. 3 ).
Having solved the issue of linker stability, we tested the specificity of activation of the AND-Gate 2 probe using a co-culture of breast tumor 4T1 cells and RAW macrophages. Cells were first incubated with DMSO or the cytotoxic agent etoposide (5 μM) for 24 h to induce apoptosis. The 6-QC, AND-Gate 2, Casp3-QC (single substrate probe for Casp3, Supplementary Fig. 4 ), and respective negative control probes were added to the cells for 2 h before acquiring images ( Fig. 2d) . As expected, none of the negative control probes were activated under any conditions while 6-QC was activated independently of apoptosis induction and AND-Gate 2 was activated only in the apoptotic cells ( Fig. 3e) . These results confirm that the AND-Gate 2 probe required processing by both proteases to produce a fluorescent product that accumulates inside macrophage lysosomes.
AND-Gate Probes have improved tumor selectivity in a mouse model of breast cancer
We next evaluated the AND-Gate 2 probe and its respective negative controls in a 4T1 mouse model of breast cancer. We chose this model because it allows direct imaging of live animals using a NIR imaging system. The tumor-specific signal can be measured relative to surrounding background tissues and tissues can be subsequently removed for quantification and determination of overall probe activation in major organs distant to the tumor site. We imaged live animals 2 h post injection of probes and found that the AND-Gate 2 probe showed strong tumor accumulation that resulted in a brighter tumor signal than the cathepsin only substrate 6-QC ( Fig. 4a) . Importantly, the negative control probes produce no visible signals confirming the linker stability observed in vitro. Quantification of total tumor fluorescence confirmed that both the AND-Gate 2 and single substrate probe 6-QC produced a significantly increased signal compared to the negative controls (D)-Phe 2 and (D)-Asp 2, and that this level of contrast over controls was several-fold higher for the AND-gate probe (Fig. 4b) . The Casp3-specific substrate probe Casp3-QC that has only the caspase half of the AND-gate substrate showed a low-level tumor signal, however it was not significantly higher than the two negative control probes. The tumor-to-background ratio (TBR) for the AND-Gate 2 was also significantly increased over the single-parameter 6-QC probe (3.0 ± 0.3 compared to 2.3 ± 0.5; Supplementary Fig. 5 ).
In order to determine the overall tumor selectivity of the probes, we excised relevant organs for ex vivo imaging and quantified the background corrected signals. We found that the fluorescent signals in excised liver, kidneys, and lung tissue was significantly reduced in the animals treated with the AND-Gate 2 compared to those treated with 6-QC ( Fig. 4c) .
Quantification of the fold change in fluorescent signals over tumor signals for each tissue confirmed the dramatic increase in selectivity of the AND-gate probe compared to the cathepsin-only 6-QC probe ( Fig. 4d) . As a further analysis of probe activation in vivo, we fixed and embedded excised tumors for cryo-sectioning and histological analysis using fluorescence microscopy ( Fig. 4e) . We stained tumor sections for CD68, a marker for macrophages, as well as for cleaved Casp3. This analysis confirmed the presences of macrophages within the 4T1 breast tumors, as has been previously described 20 . We also observed numerous regions within the tumor tissues where cells contained active Casp3. These regions of apoptotic cells were always found directly adjacent to, or co-localized with, macrophage cell populations. The brightest probe signal was always found at the intersection between macrophages and cells with active Casp3 confirming that Casp3 and Cats are both active within a tumor and generally found in close proximity making them ideal targets for use in the AND-gate strategy.
AND-gate probes have improved false positive and false negative rates in a mouse model of colorectal cancer
To further demonstrate the general applicability of the AND-gate strategy to other tumor models, we compared the performance of AND-Gate 2 to the single substrate cathepsin probe 6-QC in an apc min/+ colorectal cancer mouse model. This model provides an opportunity to test the AND-Gate probe in a spontaneous cancer model containing a genetically distinct cancer from that of the 4T1 breast tumor model. Polyps in this model are difficult to distinguish from healthy tissue by eye due to their small size. Mice containing polyps were injected with each probe and sacrificed 16 h post injection. Overall, both probes were able to fluorescently label polyps in mice after systemic injection ( Fig. 5) . Using the fluorescent signal from the probes, we chose areas of high, medium, and low fluorescent signal to be sectioned, stained for hematoxylin and eosin (H&E), and evaluated for the presence of tumor. Areas containing high or medium fluorescence intensity were expected to contain tumor while areas with low fluorescence intensity were expected to be healthy. The evaluated sections were determined to be true positive (TP), false positive (FP), true negative (TN), or false negative (FN) based on the expected and actual outcomes for the presence of tumor (Fig. 5c ). This analysis determined that the AND-Gate 2 probe had a lower false positive rate (FPR) and false negative rate (FNR) compared to 6-QC (0.25 vs 0.33 FPR and 0.19 vs 0.25 FNR). Based on this analysis, the two probes are comparable in their ability to highlight polyps in this colorectal cancer mouse model, but the AND-Gate 2 has a higher accuracy compared to the single substrate probe 6-QC.
Synthesis of 780 nm emitting AND-Gate probe and evaluation using the da Vinci ® Xi
Surgical System
To evaluate the performance of our AND-Gate probe strategy during robotic fluorescenceguided surgery, we synthesized an AND-Gate probe containing a fluorophore that has excitation and emission wavelengths compatible with the FDA approved Firefly ® detection system on the da Vinci ® Xi Surgical System. Currently, the Firefly ® fluorescence detection system is specifically tuned to the excitation/emission properties of indocyanine green (ICG, ex/em: 780/820 nm). We initially sought to synthesize an AND-Gate probe containing the conjugatable version of ICG (containing a carboxylic acid) and the respective quencher QC-1, which is non-fluorescent and has strong absorbance between 600-900 nm. However, conjugating ICG to the peptide scaffold caused unexpected reactivity issues possibly caused by aggregation or tertiary folding of the molecule. Therefore, we used a heptamethine cyanine fluorophore FNIR-Tag that was designed by the Schnermann group to resist aggregation and have better water solubility compared to ICG 32 . We conjugated the FNIR dye successfully to the α-amine on the central (D)-Glu linker and subsequently attach two QC-1 quenchers to the lysine side chains to produce AND-Gate-FNIR (Supplementary Scheme 2). Although this fluorophore has slightly lower excitation/emission maximum wavelengths compared to ICG (765/788 nm), the fluorescence can be detected by the Firefly ® detection system, albeit with lower sensitivity than for ICG. We confirmed that AND-Gate-FNIR was efficiently processed by CatL and Casp3 using the recombinant proteases in a fluorogenic substrate assay ( Supplementary Fig. 12 ). Like the Cy5 AND-Gate probes, AND-Gate-FNIR produced a fluorescent signal only after incubation with both proteases, regardless of order of addition.
We then compared the performance of AND-Gate-FNIR to the single substrate probes 6-QC-ICG and 6-QC-NIR during robotic surgery using mice bearing 4T1 breast tumors. Both single substrate probes were developed in our laboratory and contain either an ICG or Dylight780-B1 (NIR) fluorophore, which are activated by cysteine cathepsin proteases 25 . We injected mice bearing 4T1 breast tumors with probes 2 h prior to performing robotic surgery (20 nmol, I.V.). The AND-Gate-FNIR produced fluorescent contrast in the tumor compared to the surrounding tissue, which clearly highlighted the margin during surgery (Fig. 6a) . Despite using a fluorophore with lower excitation/emission wavelengths compared to ICG, the AND-Gate-FNIR had comparable fluorescent signal intensity to the 6-QC-ICG probe and much improved signal in comparison to 6-QC-NIR, which also has lower excitation/emission wavelengths than ICG (788/799 nm).
Following robotic surgery, tumors and organs from mice injected with each probe were imaged ex vivo using the LiCor Pearl imaging system to quantify the fluorescent signal.
Representative images of excised tumors and organs confirmed a reduced signal in the liver and kidneys compared to the signal found in the tumors for AND-Gate-FNIR compared to both of the 6-QC probes (Fig. 6b) . Quantification of the signal in the organs normalized to the tumor signal confirmed a significant reduction in background in the liver for mice injected with AND-Gate-FNIR compared to both 6-QC probes and a significant reduction in background for all healthy organs compared to 6-QC-NIR (Fig. 6c) .
To Further demonstrate the utility of the AND-Gate-FNIR probe, we performed a resection of a primary tumor mass and subsequently used probe fluorescence to assess the resulting tumor bed. The residual cancer cells left after excision of the primary tumor mass were not visible by white light imaging but could easily be visualized using the Firefly ® detection of the probe signal (Supplementary Movie 1; Fig. 7) . We then removed the tumor bed tissue with significant surrounding probe-negative tissue. This tissue was fixed and sectioned such that sections contained both probe positive and probe negative regions in a single slice. Analysis of the H&E stained tissues by a trained pathologist confirmed that the regions showing probe activation contain residual tumor left behind after excision, while probe negative regions contained only healthy skin cells. Thus, the AND-Gate-FNIR probe was able to accurately detect areas of residual tumor cells left behind after excision of a bulk tumor.
Discussion
The sensitive and accurate detection of tumor margins is a central goal for effective treatment of any type of solid tumor using surgery. Currently, there are a number of effective ways to image the location of a tumor in the body. However, most of the current imaging strategies are not suitable for real-time applications during surgery. Furthermore, they often depend on contrast agents that lack a level of specificity that allows them to be used in diverse cancer tissue types.
Recent efforts to address these limitations in current imaging technologies have focused on targeted contrast agents that produce fluorescent signals only within the tumor microenvironment. While this approach has proven valuable and several agents are currently in human clinical trials, there still remains a need to find new strategies to improve the selectivity of optical contrast agents so that they can be used in virtually any type of tumor resection. We and others have developed activatable 'smart probes' that turn on a fluorescent signal when processed by a protease that is highly activated in tumor tissues. These reagents provide overall high contrast in some tumor types where levels of the active protease in the surrounding normal tissues is low. Here, we outline a general strategy to generate a next-generation of optical smart probes that require sequential processing by multiple tumor-associated enzymes.
This multivariate AND-gate type sensor has the potential for highly increased tumor selectivity by incorporating substrates that are specifically processed by enzymes that exist in normal tissues but that are only found together in the tumor microenvironment. Using this strategy, background signal in healthy surrounding tissue is eliminated, resulting in high image contrast and clear margin detection even for probes with overall low signal strength.
We chose to build the first AND-ate probe using two substrates. The first is a sequence that have previously shown to work well for multiple cysteine cathepsins and that is used in our single substrate tumor imaging probe 6-QC 20, 25 . For a second substrate, we chose to use a peptide sequence that has been optimized for cleavage by Casp3 33, 34 . We chose these enzymes because of their overall distinct and non-overlapping primary sequence specificity.
Furthermore, while all tissues contain some level of active cathepsins, Casp3 is only activated in the late stages of apoptosis, which typically does not take place in healthy tissues. Multiple types of cell death are activated within tumors as the result of several factors including nutrient and oxygen starvation. Dying cells within the tumor activate infiltrating immune cells, such as macrophages that then clear the cells by lysosomal engulfment. Therefore, there exists a specific niche within the tumor microenvironment where both lysosomal and apoptotic proteases co-exist, making these proteases ideal choices for use in tumor-specific AND-gate sensors.
Because we have designed a general strategy in which the fluorescent reporter is attached to a central linker that is the final end product of probe processing, it is possible to further engineer our first generation AND-gate probes to respond to additional enzymatic processes beyond a binary set of targets. This hub and spoke model should also be amenable to further optimization of chemistry to allow production of diverse AND-gate sensors by swapping of the spokes around the central fluorescent hub. In addition, it is possible to replace the current quencher/fluorophore strategy with a FRET fluorophore pair that would allow ratiometric imaging to detect probe distribution as well as activation. This strategy would help to reduce heterogeneity of imaging signals due to differential probe distribution while also reducing background signals by allowing quantification based on a ratio of signals, which can be a large value even when probe concentrations are low. We are currently working to develop ratiometric AND-gate probes as well as multivariate versions that respond to more than two proteases.
There are a number of additional proteases that have been shown to be preferentially activated in solid tumors of diverse origins, and many of these proteases have defined substrate specificity that would make design of next generation AND-gate sensors straightforward.
In addition to using the multivariate AND-gate strategy to improve imaging contrast, it should in theory also be possible to apply this approach for selective drug delivery applications. Such a strategy would require attachment of an individual or multiple drugs to the central hub through linkages that block activity of the agents and that can be processed within a specific tissue location. One could envisage such an AND-gate therapy that releases one or more active drugs only when multiple proteases cleave the linkages tethering the molecules to one another.
We are currently exploring approaches to use the AND-gate approach for such applications.
We show here that the current AND-Gate FNIR probe is compatible with the existing FireFly detection on the widely used da Vinci Surgical System. Our results suggest that these probes could be rapidly integrated into existing surgical workflows to enable visualization of residual tumor tissue remaining after removal of a primary mass. While the 4T1 breast cancer model produces tumors that are highly encapsulated making them easily visualized by standard white light imaging, we show here that after careful removal of the primary mass, a significant number of tumor tissue remains at the skin/tumor interface. Using standard histology methods, we show that the probe accurately highlights these regions of residual cancer cells, even when those areas contain a low number of cells that cannot be detected using white light imaging.
These results suggest that the AND-gate strategy will enhance the effectiveness of tumor resections using the da Vinci Surgery System even in locations where high background signal would normally limit effective visualization of the margin.
Conclusion
Overall, the studies presented here provide a roadmap for the design of optical contrast agents that respond to unique enzymatic signatures that are indicative of a disease state. In the current design, we demonstrate the utility of the AND-gate approach using substrates that are uniquely processed by two proteases, which are both activated in the tumor microenvironment.
The design of the AND-gate protease probe used here required engineering of the linker group to prevent activation by undesired protease activities found in normal healthy tissues but ultimately resulted in a contrast agent that both improved tumor-selectivity and also increased tumor uptake resulting in a brighter overall signal. We are currently working to further optimize the central linker such that higher order probes can be rapidly generated by attachment of various substrates containing quenchers using orthogonal chemistry. This should allow synthesis of probes with high selectivity for diverse cancer types based on proteolytic signatures of those tumors. It also should, in principle, enable generation of probes that respond to other classes of enzymes that are capable of processing substrates to liberate a central fluorescent fragment.
METHODS
Chemistry Methods
See Supporting Information for synthetic protocols.
Biology Methods
General Cell Culture. 4T1 cells and RAW246.7 macrophages were cultured separately as previously describe 20, 35 Fluorogenic Substrate Assay. All proteases were active site titrated as previously described to obtain active protease concentrations 20 . The buffers used for caspases and cathepsins were made as previously described 20, 36 with probe for imaging between 7-10 days after seeding 4T1 cells. Probes were dissolved in 1X PBS (10% DMSO) and injected I.V. tail vein (100 μL, 20 nmol). Hair was removed to expose the tumors with Nair® lotion while the mice were under anesthesia 1 h prior to imaging. Mice per probe: n ≥ 5, three technical replicates where each probe was injected into at least one mouse for each replicate. Images were processed using LiCor Imaging Studio (Ver 5.2). Background corrected signal was obtained by drawing circles around tumors and then subtracting the signal directly adjacent to the tumor without hair. The areas of circles used to calculate the background corrected signal was the same for each tumor. Tumor-to-background (TBR) was calculated by placing two circles of the same size over the tumor and the exposed skin directly adjacent to the tumor and dividing the two fluorescent measurements. The cryosections were first washed with 1X PBS 3X in a slide chamber. Then, the samples were blocked with 3% w/v BSA for 24 h at 4 °C. Samples were washed 3X with 0.5% w/v BSA, then tissues were outlined with a hydrophobic pen, followed by incubation with 1:2,500 dilution of primary antibodies for CD68 (rat anti-mouse, ABD SeroTec) and cleaved Casp3 (rabbit antimouse, Cell Signaling) in 0.5% w/v BSA in 1X PBS for 24 h at 4 °C. Samples were then washed 5X with 0.5% w/v BSA in 1X PBS. Tissues were then incubated with anti-rat alexafluor488 and anti-rabbit alexafluor594 secondary antibodies (Invitrogen) diluted 1:5,000 for 1 h at RT. Tissues were washed 5X with 0.5% w/v BSA in 1X PBS, followed by 3X washes with 1X PBS. Tissues were mounted with Vectashield mounting medium containing DAPI. Tissue were embedded in paraffin and sections were cut perpendicular through the tissue, processed routinely, sectioned at 5 μm, and stained with hematoxylin and eosin (H&E). Sections were taken approximately 100 μm apart through the tissue. Figure 1 The AND-Gate strategy. (a) Schematic of a single-parameter quenched-fluorescent protease substrate that is cleaved by a single protease to produce a fluorescent fragment. These probes take advantage of higher proteolytic activity in tumors to generate contrast. (b) Schematic of the multivariate AND-Gate probe, which requires two proteolytic processing events to activate fluorescence. (c) Comparison of the single-parameter and AND-Gate probes in tumor and normal tissues. Higher contrast is generated by the AND-gate probe due to lack of activation in normal tissues which lack both protease activities. Arrowheads indicate polyps and scale bars = 100 μm. All images were contrast adjusted to show the difference between signal within polyps and normal tissue. (c) Areas in intestines with high, medium, or low fluorescence intensity were sectioned, H&E stained, and evaluated for the presence or absence of tumors. Sections were binned into four categories: true positive (contained tumor as expected, TP), false positive (unexpected tumor, FP), true negative (expected healthy tissue, TN), and false negative (unexpected healthy tissue, FN). Based on the sectioning results the false-positive rate (FPR), false-negative rate (FNR), and accuracy for each probe was calculated (n = 3 mice per probe). Rainbow plots of all data used for analysis, can be found in the Supplemental Information (Supplementary Figure 9 & 10) . 
Histological Analysis of 4T1 Tumor Sections using Confocal Fluorescence Microscopy.
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